-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
Despite the positive results of the early vaccine trials, Sanofi announced a few days ago that it will stop developing the Covid-19 vaccine based on mRNA technology
In August of this year, Sanofi acquired Translate Bio for US$3.
The mid-term trial of the vaccine yielded positive results.
A laboratory accident in 2020 delayed Sanofi's development of the new crown vaccine by at least six months
Pfizer, BioNTech, and Moderna have all modified the mRNA of their new crown vaccine products in an attempt to prevent patients from having an inflammatory response to foreign nucleic acids.
However, the huge success of Pfizer, BioNTech and Moderna vaccines is in stark contrast with CureVac's vaccine clinical data
In addition, Sanofi said it will continue to use more traditional manufacturing technology from GlaxoSmithKline to develop another Covid vaccine, which uses recombinant protein molecules to deliver antigens
Sanofi said the company's goal is to begin human trials of mRNA-based influenza vaccines next year
Sanofi and Translate Bio became the first companies to start testing seasonal mRNA influenza vaccine candidates in June, but the current research and development focus has shifted to improved quadrivalent influenza mRNA vaccines
However, Sanofi seems to be facing the risk of falling behind again
Reference source:
1.
2.
3.
